Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy

[1]  Q. Rao,et al.  Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently , 2022, Science China Life Sciences.

[2]  F. Gao,et al.  The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. , 2022, Blood.

[3]  Q. Rao,et al.  [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells]. , 2022, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[4]  Q. Rao,et al.  A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy , 2022, Experimental Hematology & Oncology.

[5]  G. Nabel,et al.  A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells , 2022, Nature.

[6]  B. Wood,et al.  SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Xiao-jun Huang,et al.  Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy , 2021, Chinese medical journal.

[8]  Hong Wang,et al.  Recent advances and challenges of bispecific antibodies in solid tumors , 2021, Experimental Hematology & Oncology.

[9]  Jianxiang Wang,et al.  A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma , 2021, Journal of immunotherapy.

[10]  Ming Liu,et al.  Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies , 2021, Journal of Hematology & Oncology.

[11]  Q. Rao,et al.  [Preparation of a novel tri-specific T cell engager targeting CD19 antigen and its anti-leukemia effect exploration]. , 2021, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[12]  Jiang F Zhong,et al.  Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant , 2020, Leukemia.

[13]  Min Wang,et al.  Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia , 2020, Journal of Hematology & Oncology.

[14]  D. Porter,et al.  Cytokine release syndrome and neurotoxicity following CAR T therapy for hematologic malignancies. , 2020, The Journal of allergy and clinical immunology.

[15]  C. Siao,et al.  Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy , 2020, Science Translational Medicine.

[16]  G. Nabel,et al.  Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation , 2019, Nature Cancer.

[17]  R. Vij,et al.  Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research , 2019, Haematologica.

[18]  Haifeng Song,et al.  A safe and potent anti-CD19 CAR T cell therapy , 2019, Nature Medicine.

[19]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  H. Dombret,et al.  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.

[21]  Leslie L Robison,et al.  Acute lymphoblastic leukaemia , 2018, Radiopaedia.org.

[22]  C. Paret,et al.  CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis , 2017, Journal of immunotherapy.

[23]  W. Klapper,et al.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.

[24]  Giovanni Martinelli,et al.  International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia , 2016, Haematologica.

[25]  Jonathan H. Esensten,et al.  CD28 Costimulation: From Mechanism to Therapy. , 2016, Immunity.

[26]  Q. Rao,et al.  Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells , 2016, Oncotarget.

[27]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[28]  R. Pazdur,et al.  FDA Approval: Blinatumomab , 2015, Clinical Cancer Research.

[29]  Jianxiang Wang,et al.  Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody. , 2013, Human gene therapy.

[30]  E. Shpall,et al.  Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  T. Hünig.  The storm has cleared: lessons from the CD28 superagonist TGN1412 trial , 2012, Nature Reviews Immunology.

[32]  L. Tuosto.  NF-κB family of transcription factors: biochemical players of CD28 co-stimulation. , 2011, Immunology letters.

[33]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..